1 SCOM 2012 GEKarolinskaPartnership Final PGM Firman Ghouze, Ph.D., Director, Cell Therapy, GE Healthcare Rolf Hultcrantz, MD, Professor, Gastroenterology and Hepatology, Karolinska Institutet, Karolinska University Hospital Johan Permert, MD, Professor, Chairman, Development and Innovation, Karolinska University HospitalFrom:AllianceRegenMedViews:2 0ratingsTime:28:54More inScience Technology Go here to see the original: 1 SCOM 2012 GEKarolinskaPartnership Final PGM - Video … Continue reading →

NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012) NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.From:RedChip Money Report GentryViews:12 0ratingsTime:04:19More inScience Technology See original here: NeoStem (NYSE MKT: NBS): RedChip Money Report (Air Date Nov. 17, 2012) - Video … Continue reading →

SAN DIEGO , Nov. 27, 2012 /CNW/ - Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, announced today the initiation of a randomized, controlled, Phase 2 multi-center study of its investigational hematopoietic stem cell therapy, ProHema, in adult patients undergoing double umbilical cord blood transplantation (dUCBT) for hematologic malignancy. The advancement of ProHema into later-stage development builds upon positive results from a Phase 1b single-center study, interactions with the U.S. Food and Drug Administration and refinements to the product manufacturing process. The previously completed Phase 1b study achieved its primary objective of demonstrating safety and tolerability. The study also established early clinical proof-of-concept trends of accelerated neutrophil recovery, improved 100-day survival and low rates of graft-versus-host disease were evident, and durable and preferential reconstitution with ProHema occurred in 10 of 12 evaluable patients. ProHema is produced through a proprietary, two-hour, ex vivo modulation process, which has been shown to significantly activate key biological pathways involved in hematopoietic stem cell homing, proliferation and survival in preclinical models. "Allogeneic umbilical cord blood transplantation holds great promise as a potentially curative treatment for children and adults with hematologic malignancies and many other life-threatening, non-malignant … Continue reading →

NEW YORK, Nov. 26, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), an emerging leader in the fast growing cell therapy industry, today announced that Company management has been invited to present at the Piper Jaffray 24th Annual Healthcare Conference. About NeoStem, Inc. NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC ("PCT"), with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company. Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being … Continue reading →